Treatment Strategies & Options

An episode of the Exploring Best Practices for Diagnosis & Management of Adult-Onset Still's Disease podcast, hosted by AOSD Podcast, titled "Treatment Strategies & Options" was published on July 9, 2021 and runs 15 minutes.

July 9, 2021 ·15m · Exploring Best Practices for Diagnosis & Management of Adult-Onset Still's Disease

0:00 / 0:00

Summary

Goals of treatment: control inflammation, prevent joint and organ damage, minimize treatment-related adverse events; relieve patient burden A wide variety of non-biologic and biologic medications are used for treatment, but are supported with limited evidence Canakinumab is the only medication approved by the US Food and Drug Administration for the treatment of patients with adult-onset Still’s disease based, in part, on the results of the phase 3 CONSIDER trial There is no standardized approach to patient monitoring, but is closely tied to the goals of treatment

Episode Description

Goals of treatment: control inflammation, prevent joint and organ damage, minimize treatment-related adverse events; relieve patient burden
A wide variety of non-biologic and biologic medications are used for treatment, but are supported with limited evidence
Canakinumab is the only medication approved by the US Food and Drug Administration for the treatment of patients with adult-onset Still’s disease based, in part, on the results of the phase 3 CONSIDER trial
There is no standardized approach to patient monitoring, but is closely tied to the goals of treatment